Free tool
FAERS Monitor: Yorvipath
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 216490 or its brand name (Yorvipath, Palopegteriparatide). Reports on generic versions are filed under their own applications.
Reports
462
Serious
163
35% of reports
Hospitalization
109
Death reported
8
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hypocalcaemia85
- hypercalcaemia51
- injection site reaction40
- nausea31
- blood calcium decreased28
- headache27
- dizziness23
- fatigue22
- paraesthesia21
- wrong technique in device usage process19
- product dose omission issue17
- vomiting15
- blood calcium increased14
- diarrhoea14
- arthralgia13
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2019 | 3 |
| 2020 | 1 |
| 2024 | 8 |
| 2025 | 98 |
| 2026 | 352 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,697 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hypocalcaemiaSignal | 85 | 205.4 | 169.4 | 17,021 |
| hypercalcaemiaSignal | 51 | 188.9 | 145.7 | 9,311 |
| blood calcium decreasedSignal | 28 | 113.6 | 79.3 | 3,009 |
| blood calcium increasedSignal | 14 | 72.8 | 43.4 | 920 |
| injection site reactionSignal | 40 | 26.5 | 19.7 | 958 |
| wrong technique in device usage processSignal | 19 | 18.5 | 11.9 | 298 |
| paraesthesiaSignal | 21 | 6.1 | 4.0 | 85 |
| product dose omission issueSignal | 17 | 2.6 | 1.7 | 16 |
| dizzinessSignal | 23 | 2.1 | 1.4 | 12 |
| headache | 27 | 2.0 | 1.4 | 12 |
| nausea | 31 | 1.8 | 1.3 | 10 |
| vomiting | 15 | 1.5 | 0.9 | 2 |
| arthralgia | 13 | 1.4 | 0.8 | 1 |
| fatigue | 22 | 1.3 | 0.9 | 1 |
| diarrhoea | 14 | 1.0 | 0.6 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.